Overview
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
Eligibility
Inclusion Criteria:
- Established atherosclerotic cardiovascular disease (ASCVD) and/or at a high risk of ASCVD
Exclusion Criteria:
- History of confirmed or suspected homozygous familial hypercholesterolemia (HoFH)
- Chronic liver disease
- Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe


